论文部分内容阅读
目的探讨倍博特对原发性高血压的临床治疗效果。方法将90例原发性高血压患者随机分为A、B、C三组,每组30例患者,病例A组患者给予口服洛活喜5～10mg/d,病例B组患者给予口服代文80～160mg/d,病例C组患者给予口服倍博特(缬沙坦氨氯地平片80mg:5mg)/d,连续给药治疗8周;比较给药前、给药4周后和给药8周后血压临床指标、降压效果和用药后不良反应发生情况。结果给药4周后三组患者血压水平较治疗前均有所改善,但病例C组下降幅度最大,差异具有统计学意义(P<0.05);给药8周后C组血压水平较其他两组下降更为明显,差异具有统计学意义(P<0.05);经过4周的治疗后,三组患者的有效率均达90%以上,经过8周的治疗后,三组患者有效率均为100%,差异不具有统计学意义(P>0.05),治疗过程中病例A组不良反应发生率10%(3/30),病例B组不良反应发生率6.7%(2/30),病例C组不良反应发生率6.7%(2/30),差异不具有统计学意义(P>0.05)。结论倍博特对原发性高血压患者,降压效果显著,且安全可靠,是治疗原发性高血压的有效药物。
Objective To investigate the clinical effect of Betocort on essential hypertension. Methods Ninety patients with essential hypertension were randomly divided into three groups: A, B and C, 30 patients in each group, patients in group A were given oral lovastatin 5 ~ 10mg / d, patients in group B were given oral diction 80 ~ 160mg / d. Patients in group C were treated with oral betaxetol (valsartan amlodipine 80mg: 5mg) / d for 8 weeks. Before administration, 4 weeks after administration and administration 8 weeks after the blood pressure clinical indicators, antihypertensive effect and adverse reactions after treatment. Results After 4 weeks of treatment, the blood pressure of the three groups improved compared with that before treatment, but the decline was the largest in group C (P <0.05). After 8 weeks of treatment, the blood pressure of group C was significantly higher than that of the other two (P <0.05). After 4 weeks of treatment, the effective rates of the three groups reached more than 90%. After 8 weeks of treatment, the effective rates of the three groups were 100%, the difference was not statistically significant (P> 0.05), the incidence of adverse reactions in case A group was 10% (3/30), the incidence of adverse reactions in case B group was 6.7% (2/30), case C The incidence of adverse reactions in group was 6.7% (2/30), the difference was not statistically significant (P> 0.05). Conclusions Betobert is effective in treating essential hypertension with significant antihypertensive effect and is safe and reliable.